WO2003046571A3 - Marqueurs biopolymeres de hp et d'apolipoproteines predictifs de la maladie d'alzheimer - Google Patents

Marqueurs biopolymeres de hp et d'apolipoproteines predictifs de la maladie d'alzheimer Download PDF

Info

Publication number
WO2003046571A3
WO2003046571A3 PCT/CA2002/001654 CA0201654W WO03046571A3 WO 2003046571 A3 WO2003046571 A3 WO 2003046571A3 CA 0201654 W CA0201654 W CA 0201654W WO 03046571 A3 WO03046571 A3 WO 03046571A3
Authority
WO
WIPO (PCT)
Prior art keywords
apolipoprotein
disease
alzheimers disease
absence
ability
Prior art date
Application number
PCT/CA2002/001654
Other languages
English (en)
Other versions
WO2003046571A2 (fr
Inventor
George Jackowski
John Marshall
Original Assignee
Syn X Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syn X Pharma Inc filed Critical Syn X Pharma Inc
Priority to AU2002336842A priority Critical patent/AU2002336842A1/en
Priority to JP2003547959A priority patent/JP2005510727A/ja
Publication of WO2003046571A2 publication Critical patent/WO2003046571A2/fr
Publication of WO2003046571A3 publication Critical patent/WO2003046571A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N5/00—Analysing materials by weighing, e.g. weighing small particles separated from a gas or liquid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation d'une combinaison d'étapes préparatoires et de méthodes de spectroscopie de masse et de détection du temps de vol pour augmenter au maximum la diversité des biopolymères pouvant être détectés dans un échantillon donné. Les biopolymères détectés dans ledit exemple sont ensuite analysés en fonction de leur faculté à présenter au moins un état pathologique donné. Les résultats obtenus permettent à un spécialiste de caractériser la présence ou l'absence d'au moins un état pathologique en fonction de la présence et/ou de l'absence dudit biopolymère, d'évaluer les risques de contracter une maladie et d'élaborer des solutions thérapeutiques à ces maladies.
PCT/CA2002/001654 2001-11-23 2002-10-31 Marqueurs biopolymeres de hp et d'apolipoproteines predictifs de la maladie d'alzheimer WO2003046571A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002336842A AU2002336842A1 (en) 2001-11-23 2002-10-31 Hp and apolipoprotein biopolymer markers predictive of alzheimers disease
JP2003547959A JP2005510727A (ja) 2001-11-23 2002-10-31 アルツハイマー病を予測するｈｐおよびアポリポタンパク質バイオポリマーマーカー

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99336401A 2001-11-23 2001-11-23
US09/993,364 2001-11-23

Publications (2)

Publication Number Publication Date
WO2003046571A2 WO2003046571A2 (fr) 2003-06-05
WO2003046571A3 true WO2003046571A3 (fr) 2004-02-19

Family

ID=25539448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001654 WO2003046571A2 (fr) 2001-11-23 2002-10-31 Marqueurs biopolymeres de hp et d'apolipoproteines predictifs de la maladie d'alzheimer

Country Status (3)

Country Link
JP (1) JP2005510727A (fr)
AU (1) AU2002336842A1 (fr)
WO (1) WO2003046571A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005101017A1 (fr) 2004-04-07 2005-10-27 Genentech, Inc. Spectrometrie de masse de conjugues d'anticorps
ES2544971T3 (es) 2008-05-13 2015-09-07 Genentech, Inc. Análisis de conjugados de fármacos y anticuerpos mediante espectrometría de masas con captura por afinidad basada en esferas
WO2012155019A1 (fr) 2011-05-12 2012-11-15 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005422A2 (fr) * 1999-07-15 2001-01-25 Biomerieux Stelhys Utilisation d'un polypeptique pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique autoimmune

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005422A2 (fr) * 1999-07-15 2001-01-25 Biomerieux Stelhys Utilisation d'un polypeptique pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique autoimmune

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GHISO J ET AL: "RESEARCH COMMUNICATION. THE CEREBROSPINAL-FLUID SOLUBLE FORM OF ALZHEIMER'S AMYLOID BETA IS COMPLEXED TO SP-40,40(APOLIPOPROTEIN J), AN INHIBITOR OF THE COMPLEMENT MEMBRANE-ATTACK COMPLEX", BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 293, no. 1, 1993, pages 27 - 30, XP000909499, ISSN: 0264-6021 *
MCGEER P L ET AL: "Distribution of clusterin in Alzheimer brain tissue.", BRAIN RESEARCH. NETHERLANDS 8 MAY 1992, vol. 579, no. 2, 8 May 1992 (1992-05-08), pages 337 - 341, XP009020153, ISSN: 0006-8993 *
NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XVII. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONS FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO", DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 7, no. 2, 28 April 2000 (2000-04-28), pages 143 - 150, XP008010899, ISSN: 1340-2838 *
SILVA DE H V ET AL: "APOLIPOPROTEIN J: STRUCTURE AND TISSUE DISTRIBUTION", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 29, no. 22, 1990, pages 5380 - 5389, XP000990797, ISSN: 0006-2960 *
WELLMANN A ET AL: "Detection of differentially expressed genes in lymphomas using cDNA arrays: Identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 96, no. 2, 15 July 2000 (2000-07-15), pages 398 - 404, XP002222896, ISSN: 0006-4971 *
WONG P ET AL: "MOLECULAR CHARACTERIZATION OF HUMAN TRPM-2/CLUSTERIN, A GENE ASSOCIATED WITH SPERM MATURATION, APOPTOSIS AND NEURODEGENERATION", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 221, no. 3, 1994, pages 917 - 925, XP001146404, ISSN: 0014-2956 *

Also Published As

Publication number Publication date
AU2002336842A1 (en) 2003-06-10
JP2005510727A (ja) 2005-04-21
WO2003046571A2 (fr) 2003-06-05

Similar Documents

Publication Publication Date Title
WO2002088722A3 (fr) Marqueur biopolymere indiquant un etat pathologique, possedant un poids moleculaire de 1350 daltons
WO2003046572A3 (fr) Chaine lourde d'immunoglobine, chaines legeres kappa et lambda d'immunoglobines, marqueurs biopolymeres predictifs de la maladie d'alzheimer
WO2003046565A3 (fr) Marqueurs du biopolymere lambda ig permettant de detecter la maladie d'alzheimer
WO2003046001A3 (fr) Marqueurs biopolymeres de proteines predictifs de l'insulinoresistance
WO2003046573A3 (fr) Marqueurs biopolymeres de proteines indicateurs de la resistance a l'insuline
WO2002088742A3 (fr) Marqueur biopolymere indiquant un etat pathologique, d'un poids moleculaire de 2937 daltons
WO2002088726A3 (fr) Marqueur biopolymere indicateur d'un etat pathologique possedant un poids de 1449 daltons
WO2003046005A3 (fr) Biopolymeres marqueurs inhibiteurs de la trypsine inter-alpha, indicateurs de la resistance a l'insuline
WO2003045991A3 (fr) Marqueurs de biopolymeres precurseurs du facteur c3 du complement permettant de predire la maladie d'alzheimer
WO2003046571A3 (fr) Marqueurs biopolymeres de hp et d'apolipoproteines predictifs de la maladie d'alzheimer
WO2003046558A3 (fr) Marqueurs biopolymeres precurseurs du complement c3 predictifs des diabetes de type ii
WO2002088743A3 (fr) Marqueur biopolymere indiquant un etat pathologique, d'un poids moleculaire de 1097 daltons
WO2002088174A3 (fr) Marqueur biopolymere presentant une masse moleculaire de 1865 daltons, indiquant un etat pathologique
WO2002088715A3 (fr) Marqueur biopolymere indiquant un etat pathologique, d'un poids moleculaire de 1465 daltons
WO2002088711A3 (fr) Marqueur biopolymere indicateur d'un etat pathologique presentant un poids moleculaire equivalent a 2021 daltons
WO2003054014A3 (fr) Marqueurs biopolymeres d'apolipoproteine indiquant la maladie d'alzheimer
WO2003046570A3 (fr) Marqueurs biopolymeres a glycoproteine et apolipoproteine predictifs de la maladie d'alzheimer
WO2002088719A3 (fr) Marqueur biopolymere de masse moleculaire de 1424 da, indicateur d'etat pathologique
WO2002088747A3 (fr) Marqueur biopolymere d'un poids moleculaire de 1845 daltons indicateur d'un etat pathologique
WO2003045984A3 (fr) Marqueurs de biopolymeres de fibronectine et de fibrinogene indiquant une resistance a l'insuline
WO2003046557A3 (fr) Marqueurs de biopolymeres hp predictifs d'une resistance a l'insuline
WO2003046564A3 (fr) Marqueurs biopolymeres proteiques predictifs de la maladie d'alzheimer
WO2003046004A3 (fr) Marqueurs biopolymeres de macroglobuline indicateurs d'une resistance a l'insuline
WO2003046566A3 (fr) Marqueurs biopolymeres pedf predictifs de la maladie d'alzheimer
WO2003046567A3 (fr) Marqueurs de biolpolymeres proteiniques permettant de predire la maladie d'alzheimer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003547959

Country of ref document: JP

122 Ep: pct application non-entry in european phase